These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25213064)

  • 21. Successful Desensitization to Isatuximab in a Patient With Refractory Multiple Myeloma and Indolent Systemic Mastocytosis. Reply to: Anaphylactic Shock due to Isatuximab and Successful Desensitization.
    Hutten EM; Roeloffzen WW; Lambeck AJ; van den Born-Bondt T; Oude Elberink HN; van de Ven AAJ
    J Investig Allergol Clin Immunol; 2024 Jun; 34(3):214-216. PubMed ID: 38888584
    [No Abstract]   [Full Text] [Related]  

  • 22. Subcutaneous panniculitis-like T-cell lymphoma with haemophagocytic syndrome during tocilizumab therapy for juvenile idiopathic arthritis.
    Nakamura H; Sugai T; Kato M; Hatanaka KC; Atsumi T
    Clin Exp Rheumatol; 2017; 35(1):174. PubMed ID: 28079502
    [No Abstract]   [Full Text] [Related]  

  • 23. Tocilizumab for rheumatoid and juvenile idiopathic arthritis.
    Bongartz T
    Lancet; 2008 Mar; 371(9617):961-3. PubMed ID: 18358909
    [No Abstract]   [Full Text] [Related]  

  • 24. Posterior reversible encephalopathy syndrome during treatment with tocilizumab in juvenile idiopathic arthritis.
    Rosa Júnior M; Borges ÉI; Fonseca APA; Fiorot JL; Balarini L; Valim V
    Arq Neuropsiquiatr; 2018 Oct; 76(10):720-721. PubMed ID: 30427514
    [No Abstract]   [Full Text] [Related]  

  • 25. Guidance on using tocilizumab for juvenile idiopathic arthritis.
    Yokota S; Imagawa T; Takei S; Murata T; Tomiita M; Itoh Y; Fujikawa S; Mori M
    Mod Rheumatol; 2011 Dec; 21(6):563-71. PubMed ID: 21597951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid desensitization.
    Dolan B
    Am J Nurs; 1982 Oct; 82(10):1532-4. PubMed ID: 6922673
    [No Abstract]   [Full Text] [Related]  

  • 27. Successful rapid desensitization to atezolizumab in delayed hypersensitivity confirmed with lymphocyte transformation test.
    Giraldo-Tugores M; Fernández-Lozano C; Carrón-Herrero A; Gajate P; Martinez-Botas J; Pueyo-López C; Solano-Solares E; Berges-Gimeno MP
    J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1649-1651. PubMed ID: 35074597
    [No Abstract]   [Full Text] [Related]  

  • 28. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?
    Tappeiner C; Heinz C; Ganser G; Heiligenhaus A
    J Rheumatol; 2012 Jun; 39(6):1294-5. PubMed ID: 22661419
    [No Abstract]   [Full Text] [Related]  

  • 29. Successful desensitization with temozolomide.
    Mónica RG; De Las Heras Gozalo M; de la Barrera EH; Dominguez JS
    Ann Allergy Asthma Immunol; 2011 Jun; 106(6):541-2. PubMed ID: 21624758
    [No Abstract]   [Full Text] [Related]  

  • 30. Successful desensitization to rabbit antithymocyte globulin in a patient with aplastic anemia.
    Bobadilla-González P; Pérez-Rangel I; García-Menaya JM; Zambonino-Carreiras MA; Cordobés-Durán C; Campano-Val FJ; López-Santamaría-Castro C; Corbacho-Hernández AJ; Fuentes-Gutiérrez I; Bajo-Gómez R
    J Investig Allergol Clin Immunol; 2012; 22(4):302-4. PubMed ID: 22812207
    [No Abstract]   [Full Text] [Related]  

  • 31. Management of hypersensitivity reactions to Tocilizumab.
    Tétu P; Hamelin A; Moguelet P; Barbaud A; Soria A
    Clin Exp Allergy; 2018 Jun; 48(6):749-752. PubMed ID: 29603809
    [No Abstract]   [Full Text] [Related]  

  • 32. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment.
    Brennan PJ; Rodriguez Bouza T; Hsu FI; Sloane DE; Castells MC
    J Allergy Clin Immunol; 2009 Dec; 124(6):1259-66. PubMed ID: 19910036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tocilizumab for systemic juvenile idiopathic arthritis.
    De Benedetti F
    N Engl J Med; 2013 Mar; 368(13):1256-7. PubMed ID: 23534566
    [No Abstract]   [Full Text] [Related]  

  • 34. Tocilizumab for systemic juvenile idiopathic arthritis.
    Hagino N; Yamaguchi K; Ohara Y
    N Engl J Med; 2013 Mar; 368(13):1256. PubMed ID: 23534567
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis.
    Zhang X; Morcos PN; Saito T; Terao K
    Expert Rev Clin Pharmacol; 2013 Mar; 6(2):123-37. PubMed ID: 23473591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful rapid desensitization to hydrochlorothiazide.
    Li J; Fernando SL
    Ann Allergy Asthma Immunol; 2013 Apr; 110(4):307-8. PubMed ID: 23535102
    [No Abstract]   [Full Text] [Related]  

  • 37. Successful heparin desensitization: a case report and review of the literature.
    Dave S; Park MA
    J Card Surg; 2008; 23(4):394-7. PubMed ID: 18598335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.
    Yokota S; Imagawa T; Mori M; Miyamae T; Aihara Y; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
    Lancet; 2008 Mar; 371(9617):998-1006. PubMed ID: 18358927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful rapid desensitization to intravenous etoposide using a 14-step protocol.
    Garcia Escallon S; Muniyappa PK; Subramanian S
    J Allergy Clin Immunol Pract; 2015; 3(4):627-8. PubMed ID: 25634221
    [No Abstract]   [Full Text] [Related]  

  • 40. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
    Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
    J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.